Detalhe da pesquisa
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
2.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510486
3.
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
J Clin Oncol
; 39(26): 2881-2892, 2021 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34138638
4.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
J Clin Oncol
; 39(1): 48-56, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33108243
5.
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Lancet Haematol
; 2(10): e417-26, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686043